![](/img/cover-not-exists.png)
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
Short, Nicholas J., Jabbour, Elias, Naqvi, Kiran, Patel, Ami, Ning, Jing, Sasaki, Koji, Nogueras-Gonzalez, Graciela M., Bose, Prithviraj, Kornblau, Steven M., Takahashi, Koichi, Andreeff, Michael, SanLanguage:
english
Journal:
American Journal of Hematology
DOI:
10.1002/ajh.25318
Date:
October, 2018
File:
PDF, 2.19 MB
english, 2018